Consultant HematologistHammersmith HospitalLondon, England, United Kingdom
OC 13.3 - Pooled Analysis of the Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Previously Treated Immune Thrombocytopenia: Phase 2 Study
Sunday, June 23, 202410:00 – 10:15 ICT
PB0700 - Identifying Unmet Needs Related to Treatment and Disease Control in Immune Thrombocytopenia (ITP): US Patient Survey
Monday, June 24, 202413:45 – 14:45 ICT
PB0716 - VAYHIT: A clinical trial program evaluating the efficacy and safety of the anti-B-cell-activating factor receptor (BAFF-R)/B-cell-depleting monoclonal antibody ianalumab in patients with primary ITP
SSC 015.8 - T cell pathophysiology in ITP
Monday, June 24, 202418:00 – 18:15 ICT
